APRE
Aprea Therapeutics, Inc.
Key Financials
Net Income
$-12599569
↑ 2.8%
Operating Income
$-13233836
↑ 7.6%
EPS (Diluted)
$-1.93
↑ 21.2%
Total Liabilities
$3.2M
↓ 56.2%
Total Assets
$15.9M
↓ 33.6%
Cash & Equivalents
$14.6M
↓ 36.1%
Operating Cash Flow
$-12894439.00
↑ 4.9%
Shareholders' Equity
$12.4M
↓ 35.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/28/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 8-K | 7/23/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | APRE |
| Company Name | Aprea Therapeutics, Inc. |
| CIK | 1781983 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 215-948-4119 |